Patents by Inventor Robyn Richardson

Robyn Richardson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BI-SPECIFIC BINDING AGENTS TARGETING SYNDECAN-1 AND FIBROBLAST GROWTH FACTOR RECEPTOR
    Publication number: 20220249679
    Abstract: Presented herein, in certain embodiments, are bi-specific binding agents comprising an antibody portion that binds specifically to syndecan-1 and a Fynomer portion that binds specifically to a Fibroblast Growth Factor Receptor 3 (FGFR3), compositions thereof and uses thereof for treating a neoplasm.
    Type: Application
    Filed: October 1, 2019
    Publication date: August 11, 2022
    Inventors: Julia CORONELLA, Robyn RICHARDSON, Anjuli TIMMER, Roland NEWMAN, Marco GYMNOPOULOS
  • Syndecan-1 (CD138) binding agents and uses thereof
    Patent number: 11242403
    Abstract: Presented herein, in certain embodiments, are compositions comprising binding agents that specifically bind to syndecan-1 and uses thereof.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: February 8, 2022
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Julia Coronella, Robyn Richardson, Anjuli Timmer, Roland Newman
  • SYNDECAN-1 (CD138) BINDING AGENTS AND USES THEREOF
    Publication number: 20200181278
    Abstract: Presented herein, in certain embodiments, are compositions comprising binding agents that specifically bind to syndecan-1 and uses thereof.
    Type: Application
    Filed: April 25, 2018
    Publication date: June 11, 2020
    Inventors: Julia CORONELLA, Robyn RICHARDSON, Anjuli TIMMER, Roland NEWMAN
  • NOVEL ANTAGONISTS OF THE HUMAN FATTY ACID SYNTHASE THIOESTERASE
    Publication number: 20070203236
    Abstract: The present invention provides for compounds of formula (I)-(XIII), as well as pharmaceutically acceptable salts thereof, metabolites thereof, pro-drugs thereof, and pharmaceutical kits that include such compounds. The present invention also provides for the compounds of formula (I)-(XIII) for use in medical therapy or diagnosis. The present invention also provides for the use of the compounds of formula (I)-(XIII) in treating cancer in mammals (e.g., humans), as well inhibiting tumor cell growth in such mammals. The present invention also provides for methods of inhibiting FAS. The methods include contacting FAS with an effective amount of a compound of formula (I)-(XIII). The present invention also provides for methods of inhibiting the TE domain of the FAS. The methods include contacting the thioesterase TE domain of the FAS with an effective amount of a compound of formula (I)-(XIII).
    Type: Application
    Filed: January 11, 2007
    Publication date: August 30, 2007
    Inventors: Jeffrey Smith, Robyn Richardson